RU2017125520A - Соединения, ингибирующие parg - Google Patents

Соединения, ингибирующие parg Download PDF

Info

Publication number
RU2017125520A
RU2017125520A RU2017125520A RU2017125520A RU2017125520A RU 2017125520 A RU2017125520 A RU 2017125520A RU 2017125520 A RU2017125520 A RU 2017125520A RU 2017125520 A RU2017125520 A RU 2017125520A RU 2017125520 A RU2017125520 A RU 2017125520A
Authority
RU
Russia
Prior art keywords
methyl
sulfonamide
methylcyclopropyl
oxobenzimidazole
thiadiazol
Prior art date
Application number
RU2017125520A
Other languages
English (en)
Russian (ru)
Other versions
RU2017125520A3 (enExample
Inventor
Элисон Е. МАКГОНЕГЛ
Аллан М. ДЖОРДАН
Богдан ВАШКОВИЧ
Колин П. ХАТТОН
Ян Д. УОДДЕЛЛ
Джеймс Р. ХИТЧИН
Кейт М. СМИТ
Ниалл М. ГАМИЛЬТОН
Original Assignee
Кэнсер Рисерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэнсер Рисерч Текнолоджи Лимитед filed Critical Кэнсер Рисерч Текнолоджи Лимитед
Publication of RU2017125520A publication Critical patent/RU2017125520A/ru
Publication of RU2017125520A3 publication Critical patent/RU2017125520A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
RU2017125520A 2014-12-19 2015-12-17 Соединения, ингибирующие parg RU2017125520A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201422771 2014-12-19
GB1422771.4 2014-12-19
PCT/GB2015/054064 WO2016097749A1 (en) 2014-12-19 2015-12-17 Parg inhibitory compounds

Publications (2)

Publication Number Publication Date
RU2017125520A true RU2017125520A (ru) 2019-01-21
RU2017125520A3 RU2017125520A3 (enExample) 2019-06-06

Family

ID=54937310

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017125520A RU2017125520A (ru) 2014-12-19 2015-12-17 Соединения, ингибирующие parg

Country Status (16)

Country Link
US (4) US10508086B2 (enExample)
EP (2) EP3233845B1 (enExample)
JP (1) JP6673920B2 (enExample)
KR (1) KR102682782B1 (enExample)
CN (2) CN112979631B (enExample)
AU (1) AU2015365602B2 (enExample)
BR (1) BR112017012707B1 (enExample)
CA (1) CA2969298C (enExample)
ES (1) ES2886471T3 (enExample)
IL (1) IL252745B (enExample)
MA (1) MA41179A (enExample)
MX (1) MX380901B (enExample)
RU (1) RU2017125520A (enExample)
SG (1) SG11201704843QA (enExample)
WO (1) WO2016097749A1 (enExample)
ZA (1) ZA201704383B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
EP3947351B1 (en) 2019-03-29 2026-03-11 Board of Regents, The University of Texas System Small molecule parg inhibitors and methods of use thereof
CA3147493A1 (en) * 2019-09-20 2021-03-25 Jr. James Clifford Sutton 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
EP4413000A1 (en) 2021-10-04 2024-08-14 FoRx Therapeutics AG N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
WO2023064619A1 (en) 2021-10-17 2023-04-20 University of South Alabama Foundation for Research and Commercialization Cancer treatment
KR20240159579A (ko) * 2022-02-14 2024-11-05 어레이즈 테라퓨틱스 인크. Parg 억제제
WO2023165571A1 (zh) * 2022-03-04 2023-09-07 上海璎黎药业有限公司 一种含五元杂芳环结构化合物、其药物组合物及应用
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
AR128846A1 (es) 2022-03-23 2024-06-19 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg
CN114685283B (zh) * 2022-04-06 2024-02-27 南京艾康生物科技有限公司 一种1-(氟甲基)环丙胺盐酸盐的制备方法
WO2023205914A1 (en) * 2022-04-28 2023-11-02 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
WO2023208092A1 (en) * 2022-04-28 2023-11-02 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
CN119403803A (zh) 2022-05-17 2025-02-07 858治疗公司 Parg抑制剂
JP2025523576A (ja) * 2022-06-29 2025-07-23 杭州聖域生物医薬科技有限公司 含窒素５，６－縮合化合物、その中間体、調製方法及び用途
CN119522220A (zh) * 2022-07-19 2025-02-25 苏州信诺维医药科技股份有限公司 含硫杂芳环化合物、其药物组合物及其用途
EP4311829A1 (en) 2022-07-28 2024-01-31 Nodus Oncology Limited Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer
AR130748A1 (es) * 2022-10-13 2025-01-15 Hanmi Pharmaceutical Co Ltd Compuesto heterobicíclico para inhibir la interacción yap-tead y composición farmacéutica que lo comprende
WO2024120519A1 (zh) * 2022-12-09 2024-06-13 捷思英达控股有限公司 Tead抑制剂、其制备方法和在医学上的应用
WO2024173234A1 (en) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibitors of parg
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds
AU2024262278A1 (en) * 2023-04-27 2025-12-18 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
EP4716532A2 (en) * 2023-05-23 2026-04-01 Quantx Biosciences US, Inc. Bicyclic heteroaryl compounds
WO2024254990A1 (zh) * 2023-06-16 2024-12-19 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
WO2025035108A2 (en) * 2023-08-10 2025-02-13 Arase Therapeutics Inc. Inhibitors of parg
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025070690A1 (ja) 2023-09-29 2025-04-03 第一三共株式会社 ３－フェニルプロピルアミン誘導体
CN121889393A (zh) 2023-10-03 2026-04-17 福克斯治疗股份公司 Parg抑制化合物
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
WO2025098445A1 (zh) * 2023-11-07 2025-05-15 南京同诺康医药科技有限公司 Parg抑制剂及其制备方法和用途
WO2025108225A1 (zh) * 2023-11-20 2025-05-30 上海复星医药（集团）股份有限公司 作为parg抑制剂的含氮三环衍生物
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025229549A1 (en) * 2024-04-30 2025-11-06 Satyarx Pharma Innovations Pvt Ltd Novel heterocyclic compounds as inhibitors of parg
WO2026022150A1 (en) 2024-07-22 2026-01-29 Forx Therapeutics Ag Parg inhibitory compounds
WO2026033475A1 (en) * 2024-08-09 2026-02-12 Avelos Therapeutics Inc. Substituted aryl or heteroaryl compound derivatives and pharmaceutical use thereof
WO2026040953A1 (zh) * 2024-08-19 2026-02-26 上海和誉生物医药科技有限公司 一种多环parg抑制剂和其应用
WO2026062066A1 (en) 2024-09-17 2026-03-26 Forx Therapeutics Ag Compounds inducing parg degradation

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1157858A (en) 1979-12-03 1983-11-29 Ikuo Ueda Quinazoline derivatives
DE4407047A1 (de) 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1131856A1 (en) 1998-11-12 2001-09-12 BAE Systems Electronics Ltd. Scanning of electromagnetic beams
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
DE19927415A1 (de) * 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7009052B2 (en) 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
WO2007014226A2 (en) * 2005-07-26 2007-02-01 The Board Of Trustees Of The University Of Illinois Compounds for the treatment of neurodegeneration and stroke
CN101374808B (zh) * 2006-01-24 2011-05-25 伊莱利利公司 孕酮受体的吲哚磺酰胺调节剂
CA2645583A1 (en) 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
EP2211854A4 (en) 2007-10-19 2011-01-12 Bipar Sciences Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
JPWO2010007944A1 (ja) * 2008-07-17 2012-01-05 旭化成ファーマ株式会社 含窒素二環性複素環化合物
CN101429191B (zh) 2008-11-03 2012-05-23 中国药科大学 取代的四氢异喹啉衍生物的用途
EA201290642A1 (ru) 2010-01-13 2013-05-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Соединения и способы
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
ES2552977T3 (es) 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
TW201307292A (zh) 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
CA2896554C (en) 2012-12-27 2019-11-05 Drexel University Novel antiviral agents against hbv infection
CA2939021C (en) 2014-02-11 2022-07-12 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
KR20190078646A (ko) 2016-11-18 2019-07-04 머크 샤프 앤드 돔 코포레이션 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체
EP3947351B1 (en) 2019-03-29 2026-03-11 Board of Regents, The University of Texas System Small molecule parg inhibitors and methods of use thereof
CA3147493A1 (en) 2019-09-20 2021-03-25 Jr. James Clifford Sutton 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
AR128846A1 (es) 2022-03-23 2024-06-19 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg

Also Published As

Publication number Publication date
WO2016097749A1 (en) 2016-06-23
KR102682782B1 (ko) 2024-07-12
JP2017538750A (ja) 2017-12-28
ZA201704383B (en) 2022-03-30
CN107295799A (zh) 2017-10-24
US10995073B2 (en) 2021-05-04
RU2017125520A3 (enExample) 2019-06-06
EP3233845A1 (en) 2017-10-25
CN112979631B (zh) 2024-09-20
SG11201704843QA (en) 2017-07-28
US10508086B2 (en) 2019-12-17
US20250223266A1 (en) 2025-07-10
IL252745A0 (en) 2017-08-31
CA2969298C (en) 2023-10-17
US12129236B2 (en) 2024-10-29
ES2886471T3 (es) 2021-12-20
EP3233845B1 (en) 2021-07-21
BR112017012707B1 (pt) 2023-10-24
NZ732394A (en) 2024-01-26
CN107295799B (zh) 2021-03-16
EP3907224A1 (en) 2021-11-10
JP6673920B2 (ja) 2020-03-25
MX2017007976A (es) 2018-03-26
CA2969298A1 (en) 2016-06-23
US20210380539A1 (en) 2021-12-09
US20180194738A1 (en) 2018-07-12
KR20170095370A (ko) 2017-08-22
MX380901B (es) 2025-03-12
MA41179A (fr) 2017-10-24
AU2015365602A1 (en) 2017-06-29
CN112979631A (zh) 2021-06-18
IL252745B (en) 2020-03-31
AU2015365602B2 (en) 2020-02-27
HK1245253A1 (zh) 2018-08-24
US20200165208A1 (en) 2020-05-28
BR112017012707A2 (pt) 2018-01-02

Similar Documents

Publication Publication Date Title
JP2017538750A5 (enExample)
RU2017124425A (ru) Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg
JP2010533158A5 (enExample)
RU2019117556A (ru) Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
JP2007510689A5 (enExample)
JP2017508766A5 (enExample)
JP2018530591A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
HRP20211960T1 (hr) Alosterični modulatori nikotinskih acetilcolinskih receptora
SI2970155T1 (en) INHIBITORS INDOLEAMIN 2,3-DIOXYGENESIS (IDO)
JP2010513444A5 (enExample)
JP2019504009A5 (enExample)
JP2011503166A5 (enExample)
JP2019519484A5 (enExample)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2007523905A5 (enExample)
JP2016523911A5 (enExample)
HRP20200440T1 (hr) 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori
JP2013516415A5 (enExample)
RU2016133626A (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
RU2016141646A (ru) Ингибиторы trka киназы, основанные на них композиции и способы
JP2010540462A5 (enExample)
JP2010534673A (ja) 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物
JP2008501673A5 (enExample)
JP2020502058A5 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191121